Critical illness is characterized by profound metabolic, inflammatory, and microcirculatory disturbances that can impair mitochondrial function across multiple organs. Excessive production of reactive oxygen species, disruption of electron transport, loss of mitochondrial membrane potential, impaired oxidative phosphorylation, and altered mitochondrial quality control may contribute to cellular energy failure, immune dysfunction, endothelial injury, and multiorgan failure. Mitochondrial-targeted antioxidants are designed to accumulate within mitochondria and neutralize oxidant stress at its principal site of generation. Agents under investigation include mitochondria-directed ubiquinone derivatives, nitroxide-based compounds, mitochondria-targeted peptides, and pharmacologically modified antioxidant molecules. Preclinical studies have shown improvements in mitochondrial respiration, endothelial function, inflammatory signaling, and tissue injury, although translation into clinical practice remains limited. Human evidence is heterogeneous and frequently restricted by small sample sizes, variable timing of administration, differences in disease phenotype, and uncertain biomarker selection. This review examines the biological rationale, clinical relevance, diagnostic considerations, treatment strategies, emerging therapies, and current guideline implications of mitochondrial-targeted antioxidants in critical illness.
Critical illness encompasses sepsis, septic shock, severe trauma, acute respiratory distress syndrome, ischemia-reperfusion injury, major surgery, and other conditions associated with systemic physiological stress. Although advances in intensive care have improved survival, mitochondrial dysfunction remains an important component of persistent organ failure and delayed recovery. Mitochondria are responsible for aerobic adenosine triphosphate production, calcium handling, redox regulation, apoptosis, and innate immune signaling. Their failure can therefore affect virtually every organ system.
Oxidative stress is not simply an excess of reactive oxygen species, but a disturbed balance between oxidant generation, antioxidant defenses, and cellular repair. Conventional antioxidant therapy may be ineffective when it does not reach the mitochondrial compartment in adequate concentrations. Mitochondrial-targeted antioxidants are engineered to exploit membrane potential, lipophilic cations, peptide transport, or selective intracellular delivery pathways. Their therapeutic objective is to reduce pathological oxidation while preserving physiological redox signaling, which is essential for host defense and cellular adaptation.
critical illness, mitochondrial dysfunction, targeted antioxidants, oxidative stress, sepsis, mitochondrial medicine, intensive care, organ failure
Sepsis and septic shock remain major causes of mortality worldwide, with substantial variation between regions, healthcare systems, and patient populations. Mitochondrial injury is frequently observed in patients with severe infection, but it also occurs after trauma, burns, cardiac arrest, transplantation, and prolonged mechanical ventilation. The burden is not limited to early mortality. Survivors may experience prolonged weakness, cognitive impairment, reduced exercise capacity, immune dysregulation, and persistent organ dysfunction, all of which may reflect incomplete restoration of cellular energetics.
The clinical expression of mitochondrial dysfunction is heterogeneous. Some patients demonstrate reduced oxygen utilization despite apparently adequate oxygen delivery, whereas others develop severe tissue hypoxia from microvascular shunting, anemia, respiratory failure, or circulatory collapse. This heterogeneity complicates therapeutic development because an intervention that benefits patients with demonstrable mitochondrial respiratory impairment may be ineffective, or potentially harmful, in patients without that phenotype. Epidemiological studies therefore need to move beyond diagnostic labels and incorporate molecular, metabolic, and physiological stratification.
During critical illness, inflammatory mediators, catecholamine excess, hypoxia, ischemia-reperfusion, and exposure to drugs or toxins can increase electron leakage from the respiratory chain. Complexes I and III are important sources of superoxide, particularly when electron transport is impaired or the mitochondrial membrane potential becomes excessively elevated. Superoxide can generate hydrogen peroxide and, in the presence of transition metals, highly reactive hydroxyl radicals. These molecules can oxidize mitochondrial DNA, respiratory-chain proteins, cardiolipin, membrane lipids, and enzymes involved in the tricarboxylic acid cycle.
Oxidative injury may produce a self-reinforcing cycle. Damaged mitochondria generate more reactive oxygen species, release mitochondrial DNA and other danger-associated molecular patterns, activate inflammasomes, and stimulate endothelial and leukocyte responses. Loss of membrane integrity can promote permeability transition, swelling, impaired ATP synthesis, and proapoptotic signaling. At the same time, mitochondrial biogenesis may be suppressed or inadequately coordinated with mitophagy. The result may be an energy-conserving state sometimes described as cytopathic hypoxia, in which cells cannot effectively use available oxygen.
Mitochondrial-targeted antioxidants seek to interrupt this cycle. Mitoquinone, for example, links a ubiquinone moiety to a lipophilic cation, allowing accumulation within the negatively charged mitochondrial matrix. SS-31 is a mitochondria-targeted peptide that interacts with cardiolipin and may stabilize the inner mitochondrial membrane. Other compounds, including mitochondria-directed nitroxides and redox-active peptides, are being evaluated for their ability to preserve electron transport, reduce lipid peroxidation, and limit inflammatory signaling. Because reactive oxygen species also function as physiological messengers, complete suppression is neither feasible nor desirable.
Risk factors for clinically important mitochondrial injury include advanced age, pre-existing renal or hepatic disease, diabetes, obesity, cardiovascular disease, malnutrition, immunosuppression, and chronic inflammatory conditions. The intensity and duration of shock, recurrent hypoxemia, severe hyperglycemia, prolonged vasopressor exposure, and repeated ischemia-reperfusion episodes may further increase oxidative burden. Mitochondrial vulnerability is also influenced by genetic variation, baseline antioxidant capacity, nutritional status, and prior exposure to mitochondrial toxicants.
Critical care interventions can modify risk. Mechanical ventilation with excessive pressures, persistent hyperoxia, transfusion-related complications, and some antimicrobial or antineoplastic agents may contribute to cellular oxidative stress in selected circumstances. These associations do not establish that standard therapies should be withheld. Rather, they support careful avoidance of iatrogenic extremes and emphasize the need for individualized assessment of oxygenation, perfusion, glucose control, nutrition, and medication exposure.
Mitochondrial dysfunction has no single pathognomonic clinical presentation. Manifestations may include persistent lactic acidosis, vasopressor-resistant shock, unexplained weakness, delayed liberation from mechanical ventilation, encephalopathy, acute kidney injury, hepatic dysfunction, myocardial depression, and impaired wound healing. In some patients, serum lactate remains elevated despite restoration of blood pressure and global oxygen delivery. This finding may reflect impaired oxygen utilization, increased glycolysis, reduced hepatic clearance, adrenergic stimulation, or ongoing tissue hypoperfusion, so it must not be attributed automatically to mitochondrial failure.
At the bedside, disproportionate organ dysfunction, poor recovery after hemodynamic stabilization, and discordance between systemic oxygen measurements and tissue function may raise suspicion. However, these findings are nonspecific and should prompt evaluation for infection, occult ischemia, medication effects, endocrine disorders, nutritional deficiencies, and ongoing circulatory abnormalities.
Diagnosis currently relies on integrating clinical assessment with conventional organ-function testing and selected research biomarkers. Lactate trends, venous-to-arterial carbon dioxide differences, oxygen extraction variables, renal and hepatic indices, echocardiographic findings, and neurological examination can help characterize the physiological state. Experimental approaches include measurement of mitochondrial DNA fragments, oxidized lipid products, redox metabolites, ATP-related signatures, circulating cell-free mitochondrial components, and mitochondrial respiration in peripheral blood cells or platelets.
These methods remain limited by preanalytical variability, uncertain reference ranges, tissue specificity, and incomplete validation against patient-centered outcomes. A biomarker may indicate mitochondrial stress without identifying a treatable lesion. For clinical practice, serial assessment is generally more informative than a single measurement, and results should be interpreted within the context of infection control, perfusion, oxygenation, nutrition, medication exposure, and organ support requirements.
The foundation of management remains rapid recognition and treatment of the underlying cause. In sepsis, this includes appropriate antimicrobial therapy, source control, individualized fluid administration, vasopressor support when indicated, and careful reassessment of perfusion. Mechanical ventilation should use lung-protective principles, while oxygen should be titrated to avoid both hypoxemia and unnecessary hyperoxia. Glycemic management, temperature control, nutritional adequacy, early mobilization, and prevention of avoidable secondary injury are also relevant to mitochondrial recovery.
Mitochondrial-targeted antioxidants should currently be regarded as investigational or adjunctive therapies rather than replacements for established critical care. Potential benefits may depend on early administration before irreversible organ injury, selection of patients with demonstrable oxidative or mitochondrial dysfunction, and dosing that achieves effective intracellular exposure without suppressing beneficial redox signaling. Safety monitoring is essential because redox-active compounds may influence immune responses, vascular tone, coagulation, drug metabolism, or cellular proliferation.
Clinical trials should use clinically meaningful outcomes such as mortality, ventilator-free days, vasopressor-free days, renal recovery, functional status, and quality of life. Biomarker changes alone are insufficient evidence of benefit. Trials should also report timing relative to shock onset, concomitant antioxidant use, nutritional interventions, renal replacement therapy, and disease phenotype, since these factors may alter pharmacokinetics and treatment response.
Recent research has moved toward precision redox medicine rather than nonspecific antioxidant supplementation. New compounds are being designed to target cardiolipin, selectively modulate complex I or III electron transfer, improve mitophagy, stimulate mitochondrial biogenesis, or preserve mitochondrial dynamics. Peptide-based agents are of particular interest because they may enter cells without relying exclusively on membrane potential and may stabilize mitochondrial membranes under ischemic conditions.
Combination strategies are also under evaluation. A mitochondrial antioxidant may be paired with agents that restore substrate utilization, improve endothelial function, reduce excessive inflammation, or promote tissue repair. Metabolic interventions involving ketone utilization, controlled nutritional support, or modulation of the nicotinamide adenine dinucleotide redox state have a mechanistic rationale, but their clinical value requires rigorous confirmation. Pharmacokinetic studies using tissue-relevant biomarkers and adaptive trial designs may help identify responders and avoid exposing patients without the relevant biological abnormality.
Current major critical care and sepsis guidelines emphasize early treatment of infection, hemodynamic stabilization, appropriate oxygenation and ventilation, source control, and prevention of secondary organ injury. They do not generally recommend routine administration of mitochondrial-targeted antioxidants because definitive evidence for mortality reduction or durable functional benefit is not yet available. Conventional antioxidant supplements should not be used as substitutes for evidence-based resuscitation or organ support.
Clinicians considering investigational therapy should follow institutional research protocols, ensure informed consent where applicable, and assess interactions with standard treatment. Future recommendations will require adequately powered randomized trials, reproducible patient-selection criteria, validated mitochondrial biomarkers, and transparent reporting of adverse events. Guideline committees should also distinguish between biologically promising agents and therapies supported by proven clinical outcomes.
Mitochondrial injury is a plausible and clinically important contributor to organ dysfunction in critical illness, but its manifestations are complex and heterogeneous. Mitochondrial-targeted antioxidants offer a rational strategy for reducing pathological oxidative damage while preserving cellular energy production and membrane integrity. Preclinical evidence is encouraging, yet clinical translation remains incomplete because optimal timing, patient selection, dosing, biomarkers, and long-term outcomes are not established. At present, these agents should be considered investigational adjuncts within carefully designed clinical studies. Progress will depend on integrating mitochondrial biology with bedside physiology, precision phenotyping, and outcomes that matter to patients, including survival, organ recovery, functional independence, and quality of life.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation